ResMed Inc. (CHESS) Upgraded to Outperform by Commonwealth Bank (RMD)
ResMed Inc. (CHESS) (ASX:RMD) was upgraded by Commonwealth Bank to an “outperform” rating in a research note issued on Wednesday, Analyst Ratings Net reports. The firm currently has a $6.24 price objective on the stock, up from their previous price objective of $5.80.
Shares of ResMed Inc. (ASX:RMD) traded down 8.31% on Wednesday, hitting A$5.410. 23,519,468 shares of the company’s stock traded hands. ResMed Inc. has a 52 week low of A$3.210 and a 52 week high of A$5.680. The stock has a 50-day moving average of A$5.36 and a 200-day moving average of A$4.86. The company has a market cap of A$7.685 billion and a price-to-earnings ratio of 28.10.
A number of other firms have also recently commented on RMD. Analysts at Goldman Sachs Group Inc. reiterated a “neutral” rating on shares of ResMed Inc. (CHESS) in a research note to investors on Tuesday, October 22nd. Separately, analysts at UBS AG reiterated a “buy” rating on shares of ResMed Inc. (CHESS) in a research note to investors on Wednesday, August 21st. They now have a $415.00 price target on the stock. Finally, analysts at UBS AG reiterated a “buy” rating on shares of ResMed Inc. (CHESS) in a research note to investors on Tuesday, August 13th. They now have a $415.00 price target on the stock.
ResMed Inc, (ASX:RMD) is a holding company for the ResMed Group.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.